Zobrazeno 1 - 10
of 43
pro vyhledávání: '"John E. Souness"'
Autor:
Kenneth Page, Stephen D. Pickett, Frank Halley, Iain Mcfarlane Mclay, Jeffrey Mckenna, John E. Souness, Collis Alan John, Imtiaz Ahmed
Publikováno v:
Journal of Medicinal Chemistry. 45:2173-2184
Previously we reported the identification of RPR200765A, a potent orally bioavailable pyridine-imidazole inhibitor of p38 mitogen-activated protein (MAP) kinase which suppressed paw swelling and joint pathology in streptococcal cell wall-induced arth
Autor:
Nicola E. Wilsher, Andrew J. Ratcliffe, Brenda J. Burton, Collis Alan John, Maria G. Belvisi, Iain Mcfarlane Mclay, Chris Maslen, Simon Phipps, Martyn Foster, Kenneth Page, Michael F. Kelley, Bryan Slater, Stephen E Webber, Jayyosi Zaid, Kenneth Pollock, V. Benning, Alex Constan, Elisabeth J. Redford, David J Hele, Jeffrey Mckenna, Glen K. Miller, Véronique Thybaud, Barry Porter, Frank Halley, Marie-Claude Ouldelhkim, Mark A. Birrell, John E. Souness
Publikováno v:
Bioorganic & Medicinal Chemistry. 9:537-554
RPR132331, a 2-(2-dioxanyl)imidazole, was identified as an inhibitor of tumour necrosis factor (TNF)alpha release from lipopolysaccharide (LPS)-stimulated human monocytes. An intensive programme of work exploring the biology, toxicity and physical ch
Autor:
Stevan W. Djuric, Rose Mathew, Richard Labaudiniere, Paul Joseph Cox, John E. Souness, Ken M. Page, Joanne Uhl, Bruce Miller, Christopher Hulme, Fu Chih Huang, Mercy Ramanjulu, Kevin J. Moriarty, Jeffrey Travis
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 8:3053-3058
This communication describes the synthesis and in vitro and in vivo evaluation of a novel potent series of phosphodiesterase type (IV) (PDE4) inhibitors. Several of the compounds presented possess low nanomolar IC50's for PDE4 inhibition and excellen
Autor:
Hanney Barbara A, John E. Souness, Dennis Sweeney, Stevan W. Djuric, Joseph G. Bruno, Mcgarry Daniel G, Poli Gregory B, Jeffrey Travis, John R. Regan, Shelly Bower, Bruce Miller
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 8:2737-2742
A new family of PDE4 inhibitors based on a benzimidazole framework is described. Several of these compounds are orally bioavailable and show efficacy in in vivo models of inflammatory disease.
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 8:175-178
The following letter presents the synthesis and in vitro evaluation of a novel quaternary substituted series of phosphodiesterase type (IV) (PDE4) inhibitors. The compounds represent conformationally constrained analogues of the Celltech PDE IV inhib
Publikováno v:
British Journal of Pharmacology. 121:743-750
We have investigated the suppressive effects of rolipram, RP 73401 (piclamilast) and other structurally diverse inhibitors of cyclic AMP-specific phosphodiesterase 4 (PDE4) on interleukin (IL)-2 generation from Balb/c mouse splenocytes exposed to the
Autor:
Christopher Maslen, Miriam Griffin, Lisa C. Scott, John E. Souness, Jan-Anders Karlsson, Palfreyman Malcolm Norman, Kenneth Pollock, Karen Ebsworth
Publikováno v:
British Journal of Pharmacology. 118:649-658
1. We have investigated the inhibitory effects of RP 73401 (piclamilast) and rolipram against human monocyte cyclic AMP-specific phosphodiesterase (PDE4) in relation to their effects on prostaglandin (PG)E2-induced cyclic AMP accumulation and lipopol
Autor:
Ashton Michael John, Palfreyman Malcolm Norman, Andrew J. Ratcliffe, Sukanthini Thurairatnam, Nigel Vicker, Garry Fenton, Jan-Anders Karlsson, David Raeburn, John E. Souness, Cook David Charles
Publikováno v:
Journal of Medicinal Chemistry. 37:1696-1703
The syntheses and biological activities of a number of benzamide derivatives, designed from rolipram, which are selective inhibitors of cyclic AMP-specific phosphodiesterase (PDE IV), are described. The effects of changes to the alkoxy groups, amide
Autor:
John E. Souness, Lisa C. Scott, David Raeburn, Mark A. Giembycz, Adrian Tomkinson, Maria Elena Villamil
Publikováno v:
British Journal of Pharmacology. 111:1081-1088
1. The possible role of cyclic AMP phosphodiesterase (PDE) in the inhibitory actions of ibudilast on tracheal smooth muscle contractility and eosinophil thromboxane generation was investigated. 2. Ibudilast was a non-selective inhibitor of partially
Autor:
Jan-Anders Karlsson, Andrew J. Ratcliffe, Cook David Charles, Palfreyman Malcolm Norman, Garry Fenton, Sukanthini Thurairatnam, Ashton Michael John, Nigel Vicker, John E. Souness, David Raeburn
Publikováno v:
ChemInform. 25
The syntheses and biological activities of a number of benzamide derivatives, designed from rolipram, which are selective inhibitors of cyclic AMP-specific phosphodiesterase (PDE IV), are described. The effects of changes to the alkoxy groups, amide